2025 Platelet Transfusion Thresholds: When to Transfuse and When Not to Transfuse – Chokri Ben Lamine
Chokri Ben Lamine, Assistant Consultant at King Faisal Specialist Hospital and Research Center, shared a post on X about a recent article by Ryan A. Metcalf et al., published in JAMA, adding:
”2025 AABB/ICTMG Platelet Transfusion Thresholds
Nonbleeding chemotherapy / allo-HSCT: transfuse if platelet count is less than 10 × 10⁹/L
Adult critical illness, no major bleeding: transfuse if platelet count is less than 10 × 10⁹/L
Lumbar puncture: transfuse if platelet count is less than 20 × 10⁹/L
CVC insertion at compressible site (IJ/femoral): transfuse if platelet count is less than 10 × 10⁹/L
Interventional radiology:
- Low-risk procedure: transfuse if platelet count is less than 20 × 10⁹/L
- High-risk procedure: transfuse if platelet count is less than 50 × 10⁹/L
- Major non-neuraxial surgery: transfuse if platelet count is less than 50 × 10⁹/L
- Preterm neonate without major bleeding: transfuse if platelet count is less than 25 × 10⁹/L
Autologous SCT or aplastic anemia, nonbleeding adults: routine prophylactic transfusion not recommended
Dengue without major bleeding: platelet transfusion not recommended
Nonoperative ICH with platelet count greater than 100 × 10⁹/L, including antiplatelet use: platelet transfusion is not recommended.
Central-line removal is not specifically addressed; the threshold of less than 10 × 10⁹/L applies to insertion at compressible sites, not to removal.
Clinical bleeding, coagulopathy, medications, catheter site/type, and ability to apply compression should guide removal.
Platelet Transfusion – JAMA 2025.pdf. ”
Title: 2025 AABB and ICTMG International Clinical Practice Guidelines
Authors:Ryan A. Metcalf, Susan Nahirniak, Gordon Guyatt, Aarti Bathla, Sandra K. White, Arwa Z. Al-Riyami, Rachel C. Jug, Ursula La Rocca, Jeannie L. Callum, Claudia S. Cohn, Abe DeAnda, Robert A. DeSimone, Allan Dubon, Lise J. Estcourt, Daniela C. Filipescu, Mark K. Fung, Ruchika Goel, Aaron S. Hess, Heather A. Hume, Richard M. Kaufman, Peter Kranke, Vernon J. Louw, Morten H. Møller, Michael F. Murphy, Jennifer A. Muszynski, Cian J. O’Kelly, Monica B. Pagano, Gopal K. Patidar, Katerina Pavenski, Jacqueline N. Poston, Nabiha H. Saifee, Moritz Stolla, Zbigniew M. Szczepiorkowski, Aaron A. R. Tobian, Raman Uberoi, Jonathan Waters, Brittney Williams, Erica M. Wood, Nicole D. Zantek, Michelle P. Zeller, Brenda J. Grossman, Simon J. Stanworth.

Stay updated on all scientific advances with Hemostasis Today.
-
Sep 9, 2026, 17:57CRISPR/Cas Gene Editing in β-Thalassemia: From Molecular Correction to Clinical Reality
-
Sep 9, 2026, 17:38Cardiovascular Health in Bleeding Disorders – EHC
-
Sep 9, 2026, 17:33Manasvi Shah: Co-Inheritance of Alpha Globin Gene Multiplication With Beta Globin Gene Abnormalities
-
Sep 9, 2026, 17:29Christina Crossette-Thambiah: One of the Largest Studies to Date in Antiphospholipid Syndrome
-
Sep 9, 2026, 17:25Alan Nurden: A miR-146a Variant Reveals a New Pathway Linking Platelet Metabolism and Thrombosis
-
Sep 9, 2026, 17:17When Is Thrombophilia Testing Appropriate and How Can the Evidence Guide Clinical Care? – ISTH
-
Sep 9, 2026, 16:07Zahra Safarzadeh: From Novel F8 Variant to Clinical Significance
-
Sep 9, 2026, 16:00Maximo Agustin Schiavone: HDL Beyond Cholesterol – Linking Lipids and Immunity
-
Sep 9, 2026, 15:56Abdul Mannan: When Antiseizure Drugs Alter DOAC Risk